Riphah Institute of Pharmaceutical Sciences, Riphah International University, Raiwind Campus, Lahore, Pakistan.
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Raiwind Campus, Lahore, Pakistan; Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
J Ethnopharmacol. 2025 Jan 30;337(Pt 2):118905. doi: 10.1016/j.jep.2024.118905. Epub 2024 Oct 5.
Traditional herbal remedies have been used for treating nephrolithiasis, but the relevant scientific evidence is limited. Zaleya pentandra (L.) C. Jeffrey is traditionally used for the prevention of kidney stones in various cultures. However, its efficacy has not been scientifically studied.
This study aimed to investigate the antiurolithic activity of Zaleya pentandra, and validate its traditional used for preventing kidney stones.
The crude ethanolic extract of Z. pentandra (Zp.Crd) was evaluated through in vitro and in vivo studies. In vitro experiments assessed its impact on crystal count and morphology in metastable calcium oxalate solutions. In vivo studies involved diuretic and ethylene glycol-induced calcium oxalate crystal formation in male Wistar rats.
Zp.Crd transforms calcium oxalate crystals from harmful calcium oxalate monohydrate (COM) to calcium oxalate dihydrate (COD). In vivo, Zp.Crd exhibited dose-dependent (30-300 mg/kg) diuretic activity in rats by significantly increasing urinary sodium (Na) and potassium (K) excretion, similar to the standard diuretic hydrochlorothiazide (HCT). In the urolithiasis model, Zp.Crd exhibited dose-dependent antiurolithic effects by reducing kidney crystals and significantly altering lithogenic factors induced by ethylene glycol, including crystalluria, oxaluria, calcium, creatinine, and urea, in the urine and serum of treated rats. Zp.Crd also exhibited antioxidant effects, effectively combating oxidative lithogenic stress in rats.
Zp.Crd has been shown to demonstrate antiurolithic activity against CaOx stones through CaOx crystal inhibition, diuretic activity, antioxidant properties, hypocalciuric effects, and hypercitrauric actions. The findings underscore Zp.Crd's potential as a viable alternative or supplemental therapy to current urolithiasis treatments, paving the door for further clinical trials and its inclusion into modern medical practices.
传统草药疗法已被用于治疗肾结石,但相关的科学证据有限。Zaleya pentandra(L.)C. Jeffrey 在各种文化中传统上被用于预防肾结石。然而,其疗效尚未经过科学研究。
本研究旨在研究 Zaleya pentandra 的抗结石活性,并验证其预防肾结石的传统用途。
Z. pentandra 的粗乙醇提取物(Zp.Crd)通过体外和体内研究进行了评估。体外实验评估了其对亚稳态草酸钙溶液中晶体计数和形态的影响。体内研究涉及雄性 Wistar 大鼠的利尿和乙二醇诱导的草酸钙晶体形成。
Zp.Crd 将草酸钙晶体从有害的草酸钙一水合物(COM)转化为草酸钙二水合物(COD)。在体内,Zp.Crd 在大鼠中表现出剂量依赖性(30-300mg/kg)的利尿活性,显著增加尿钠(Na)和钾(K)排泄,与标准利尿剂氢氯噻嗪(HCT)相似。在结石形成模型中,Zp.Crd 通过降低肾脏晶体并显著改变乙二醇诱导的成石因素(包括尿结晶、尿草酸、钙、肌酐和尿素)来表现出剂量依赖性的抗结石作用。Zp.Crd 还表现出抗氧化作用,有效对抗大鼠的氧化成石应激。
Zp.Crd 已被证明通过抑制 CaOx 晶体、利尿活性、抗氧化特性、低钙尿作用和高柠檬酸作用来发挥抗 CaOx 结石的抗结石活性。这些发现强调了 Zp.Crd 作为当前肾结石治疗的可行替代或补充疗法的潜力,为进一步的临床试验和将其纳入现代医学实践铺平了道路。